{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:52:36Z","timestamp":1777650756007,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA223231"],"award-info":[{"award-number":["R01 CA223231"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clgc.2020.03.003","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T22:42:31Z","timestamp":1584139351000},"page":"252-257.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy"],"prefix":"10.1016","volume":"18","author":[{"given":"Lana","family":"Hamieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel L.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2020.03.003_bib1","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clgc.2020.03.003_bib2","first-page":"587","article-title":"NCCN Guidelines updates: management of metastatic kidney cancer","volume":"17","author":"Jonasch","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2020.03.003_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrurol.2015.260","article-title":"A\u00a0river model to map convergent cancer evolution and guide therapy in RCC","volume":"12","author":"Wei","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2020.03.003_bib4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2020.03.003_bib6","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/annonc\/mdr533","article-title":"Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy","volume":"23","author":"Heng","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2020.03.003_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/1471-2407-11-295","article-title":"Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma","volume":"11","author":"Busch","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2020.03.003_bib8","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1586\/era.12.81","article-title":"Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science","volume":"12","author":"Porta","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clgc.2020.03.003_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ejca.2012.02.048","article-title":"Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma","volume":"48","author":"Seidel","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2020.03.003_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/13543784.2014.871259","article-title":"Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma","volume":"23","author":"Sonpavde","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clgc.2020.03.003_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JOP.2016.011809","article-title":"Therapeutic strategies for patients with metastatic renal cell carcinoma in whom first-line vascular endothelial growth factor receptor-directed therapies fail","volume":"12","author":"Malouf","year":"2016","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clgc.2020.03.003_bib12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2020.03.003_bib13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2147\/TCRM.S126910","article-title":"Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma","volume":"13","author":"Leonetti","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clgc.2020.03.003_bib14","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1158\/1078-0432.CCR-13-2345","article-title":"Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy","volume":"20","author":"Voss","year":"2014","journal-title":"Clin Can Res"},{"key":"10.1016\/j.clgc.2020.03.003_bib15","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1172\/JCI86120","article-title":"Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin","volume":"126","author":"Xu","year":"2016","journal-title":"J Clin Investig"},{"key":"10.1016\/j.clgc.2020.03.003_bib16","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.celrep.2017.02.074","article-title":"The SWI\/SNF protein PBRM1 restrains VHL-loss-driven clear cell renal cell carcinoma","volume":"18","author":"Nargund","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.clgc.2020.03.003_bib17","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2020.03.003_bib18","series-title":"Lenvima\u00ae (lenvatinib) [Prescribing Information]","year":"2019"},{"key":"10.1016\/j.clgc.2020.03.003_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-013-2339-y","article-title":"A\u00a0phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)","volume":"73","author":"Molina","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2020.03.003_bib20","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2020.03.003_bib21","first-page":"638747","article-title":"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J\u00a0Thyroid Res"},{"key":"10.1016\/j.clgc.2020.03.003_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2045-824X-6-18","article-title":"Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage","volume":"6","author":"Yamamoto","year":"2014","journal-title":"Vasc Cell"},{"key":"10.1016\/j.clgc.2020.03.003_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clgc.2020.03.003_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cas.13169","article-title":"Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus","volume":"108","author":"Matsuki","year":"2017","journal-title":"Cancer Sci"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767320300525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767320300525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:10Z","timestamp":1761564850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767320300525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1558767320300525"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2020.03.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2020.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}